Today: 29 April 2026
Denison Mines stock drops 4% as uranium shares slide on fresh supply news — what to watch next

Denison Mines stock drops 4% as uranium shares slide on fresh supply news — what to watch next

NEW YORK, Feb 3, 2026, 09:32 EST — Regular session

  • Denison Mines shares fell early Tuesday, moving with a broader pullback in uranium-linked stocks.
  • Traders weighed softer uranium pricing and new supply signals.
  • Focus is on pending Canadian federal approvals that could unlock a construction start this quarter.

Shares of Denison Mines Corp (DNN) fell about 4.4% to $3.78 in early New York trading on Tuesday.

The move tracked losses in the uranium complex, with Cameco down about 2.6%, Uranium Energy off roughly 5.4% and the Global X Uranium ETF lower by about 3.2%.

Uranium equities have been trading on macro headlines, and Tuesday’s early tone followed fresh supply news out of Uzbekistan. The country said it lifted uranium production to 7,000 metric tons in 2025 and plans four new uranium mines for development in 2026, according to a Reuters report.

In pricing, UxC Uranium U3O8 futures on CME showed nearby contracts around the $99-per-pound area.

Denison is a Canada-based uranium explorer and developer focused on Saskatchewan’s Athabasca Basin, with its main growth project at Wheeler River. It holds a 95% interest in Wheeler River, which hosts the Phoenix and Gryphon deposits, according to Reuters data.

In a Jan. 2 update, Denison said its proposed Phoenix in-situ recovery (ISR) mine was ready to move to a final investment decision, pending final regulatory approvals. ISR is a well-based mining method that dissolves uranium underground and pumps it to the surface for processing. Chief Executive David Cates said the company “stands ready to make a final investment decision and commence construction” of the Phoenix ISR mine, and the company reiterated a mid-2028 first-production target if approvals arrive in the first quarter. Denison Mines Corp.

That timetable matters because Denison is still in the build-and-permit phase. For stocks like this, the commodity tape sets the daily mood, but permitting can change the story in a hurry.

There are risks either way. Federal decisions can slip, and any further easing in uranium prices would test sentiment, especially for developers without near-term cash flow from production.

Traders will be watching whether the broader uranium pullback keeps spreading, and whether sector moves stay tied to supply headlines rather than company specifics.

For Denison, the next clear marker is progress toward the remaining federal approvals it has said it needs before it can start construction on Phoenix in the first quarter of 2026.

Stock Market Today

  • Humana Stock Dips Over 2% Amid Profit Forecast Revision
    April 29, 2026, 9:26 AM EDT. Humana Inc. (HUM) stock dropped more than 2% premarket after the health insurer maintained its adjusted full-year profit forecast at $9 per share but lowered its nonadjusted earnings estimate to at least $8.36 from $8.89. The company reported a 23% rise in first-quarter revenue and adjusted earnings per share beating expectations. However, charges from a multiyear transformation program to realign costs and operations weighed on results. Rising medical and pharmaceutical expenses, coupled with tighter government rules on Medicare Advantage payments, have pressured the sector. Humana, a major Medicare Advantage provider, faces ongoing margin challenges. Year to date, Humana shares have fallen about 13% amid these industry headwinds.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
SpaceX buys Musk’s xAI in record $1.25 trillion deal as space stocks jump premarket
Previous Story

SpaceX buys Musk’s xAI in record $1.25 trillion deal as space stocks jump premarket

Nvidia stock drops on OpenAI chip doubts as investors brace for earnings
Next Story

Nvidia stock drops on OpenAI chip doubts as investors brace for earnings

Go toTop